Atossa Genetics (NASDAQ:ATOS) Price Target Raised to $8.00

by · The Cerbat Gem

Atossa Genetics (NASDAQ:ATOS – Free Report) had its price target raised by Ascendiant Capital Markets from $7.75 to $8.00 in a research note released on Monday,Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts have also commented on ATOS. Zacks Research lowered shares of Atossa Genetics from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Atossa Genetics presently has a consensus rating of “Hold” and an average target price of $6.33.

View Our Latest Stock Analysis on Atossa Genetics

Atossa Genetics Stock Performance

NASDAQ ATOS opened at $0.85 on Monday. The stock has a market cap of $109.79 million, a P/E ratio of -3.54 and a beta of 0.95. Atossa Genetics has a fifty-two week low of $0.55 and a fifty-two week high of $1.30. The stock has a 50 day simple moving average of $0.88 and a two-hundred day simple moving average of $0.85.

Atossa Genetics (NASDAQ:ATOS – Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). Sell-side analysts predict that Atossa Genetics will post -0.22 earnings per share for the current year.

Hedge Funds Weigh In On Atossa Genetics

Several large investors have recently made changes to their positions in ATOS. Hudson Bay Capital Management LP purchased a new stake in shares of Atossa Genetics in the 2nd quarter worth approximately $26,000. Gallagher Capital Advisors LLC bought a new stake in Atossa Genetics in the third quarter worth $27,000. JPMorgan Chase & Co. grew its stake in shares of Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after acquiring an additional 35,474 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Atossa Genetics in the second quarter worth $49,000. Finally, Bank of America Corp DE increased its holdings in shares of Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after acquiring an additional 35,629 shares in the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Further Reading